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Abstract
Background: Lymphopenia is associated with adverse prognosis in chronic disease states that are 
related to immune dysregulation. We aimed to determine the association between lymphopenia and 
mortality in patients presenting to coronary angiography and investigate whether elevated red blood 
cell distribution width (RDW), an established cardiovascular prognostic marker, further refines risk 
stratification.
Methods: Retrospective analysis of patients undergoing coronary angiography for evaluation or 
treatment of coronary artery disease between 2003 and 2018. Mortality risk associated with relative 
(1000–1500/μL) or severe (< 1000/μL) lymphopenia was analyzed using adjusted Cox proportional 
hazards regression models.
Results: Overall, 15,179 patients aged 65 ± 12 years underwent coronary angiography. During  
a median follow-up of 8 years, 4253 patients died. Compared to normal lymphocyte count, the adjusted 
hazard ratio (HR) for mortality was 1.31 (95% confidence interval [CI] 1.21–1.41) and 1.97 (95% CI 
1.75–2.22) for relative and severe lymphopenia, respectively. The increase in mortality associated with 
severe lymphopenia was significant in patients presenting in the non-acute setting (HR 2.18, 95% CI 
1.74–2.73), ST-segment elevation myocardial infarction (STEMI) (HR 1.59, 95% CI 1.15–2.21), or 
unstable angina/non-STEMI (HR 2.00, 95% CI 1.70–2.34); p-value for interaction 0.626. The as-
sociation of lymphopenia with mortality remained significant after additional adjustment to RDW. 
High RDW (> 14.5%) was associated with reduced survival, and it improved the predictive accuracy 
of lymphocytes count with an increase in Harrell’s Concordance statistic from 0.634 (SE = 0.005) to 
0.672 (SE = 0.005), p < 0.001. 
Conclusions: Lymphopenia is associated with increased risk of mortality during long-term follow-up 
in patients undergoing coronary angiography, regardless of the coronary presentation. High RDW may 
enhance the predictive ability of lymphopenia. (Cardiol J)
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Lymphopenia was demonstrated in observational 
studies to be associated with malignancies, infections, 
systemic autoimmune diseases, and worse clini-
cal outcomes [1–5]. Early studies have shown that 
a low relative lymphocyte count, measured as the 
percentage of total leukocytes, is inversely associa-
ted with the risk of cardiovascular disease (CVD) 
states, particularly heart failure [6–10]. More recent 
findings further suggest that the measurement of 
absolute lymphocyte count by itself may risk stratify 
for mortality in the setting of the general population, 
especially when associated with other immunohema-
tologic abnormalities [11, 12]. However, the extent 
to which absolute lymphopenia is associated with 
survival in patients with coronary artery disease 
(CAD) is less known [13]. In the current study, we 
aimed to investigate the association between absolute 
lymphocyte count and mortality in the real-world 
clinical practice of patients presenting to coronary 
angiography for evaluation and treatment of CAD, 
with both acute and non-acute coronary syndromes 
(ACS). In addition, we wished to examine whether 
elevated red blood cell distribution width (RDW), 
which has emerged as a useful prognostic parameter 




Retrospective analysis of the cardiac cath-
eterization laboratory database at Carmel Medical 
Center, Haifa, Israel, between January 2000 and 
December 2018, was performed. Included were 
patients who were referred to coronary angiogra-
phy for the assessment and/or treatment of CAD. 
Only the first angiography of each patient during 
the study period was included. This analysis was 
restricted to patients who are members of the Clalit 
Health Service (CHS), the largest non-for-profit 
health care provider in Israel, for whom we had 
full access to outcomes data during follow-up and 
other variables that were not originally collected 
at the time of coronary angiography. Patients with 
elevated lymphocyte count > 5000/μL and patients 
in whom laboratory values of white blood cells and 
red cell distribution width (RDW) counts in the 
year prior to angiography were unavailable were 
excluded. Final study population included 15,179 
patients.  
The study population was classified into three 
groups of angiographic indications: (a) unsta-
ble angina pectoris (UAP) or acute non-ST-seg-
ment elevation myocardial infarction (NSTEMI), 
(b) acute ST-segment elevation myocardial infarc-
tion (STEMI), and (c) evaluation and/or treatment 
of CAD with stable clinical presentation (non-
ACS). The primary study endpoint was long-term 
mortality. The cause of death was not consistently 
available, and therefore we included all-cause and 
not cardiovascular death. Data on vital status was 
retrieved from the Ministry of the Interior. Cohort 
participants were followed up until reaching the 
occurrence of study outcome or end of follow-up 
in December 2019, whichever came first. 
The study database was approved by Carmel 
Medical Center Ethics Committee with waiving of 
the need for individual patient consent due to the 
retrospective nature of the study.
Study variables and definition of terms
Demographic data, clinical variables, risk 
factors, and comorbidities were most often pro-
spectively collected from patients’ medical files 
at the time of coronary angiography. Data that 
was not originally collected were retrieved from 
computerized database of CHS. The results of all 
complete blood cell counts performed during the 
year prior to the date of coronary angiography were 
retrieved from the CHS laboratory database. We 
used 1-year median levels to calculate the absolute 
lymphocyte count, neutrophil-to-lymphocyte ratio 
(NLR), and RDW, in order to assess their associa-
tion with mortality. The absolute lymphocyte count 
was evaluated in three ways: (a) classification to 
normal lymphocyte count > 1500/μL (reference 
category); relative lymphopenia 1000–1500/μL; 
severe lymphopenia < 1000/μL, (b) quintiles of 
lymphocyte count with the highest quintile serving 
as reference, and (c) lymphocyte levels included in 
the model as a continuous variable. For the purpose 
of the current study, elevated RDW values were 
defined as > 14.5% [15]. 
Data analysis
Continuous data are reported as means and 
standard deviation or median and interquartile 
range (IQR), and categorical variables as numbers 
and percentages. One-way ANOVA test was used 
to compare continuous variables and c2 to compare 
categorical variables. For each lymphocytes group, 
the number of events and the incidence rates of 
death per 100 person-years were calculated. Me-
dian follow-up was estimated using subjects alive 
at end of follow-up. Kaplan-Meier curves were used 
to estimate the long-term cumulative incidence of 
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death according to the lymphocyte count catego-
ries, with comparison between curves performed 
using the log-rank test. The association between 
lymphocyte count and mortality over time was 
evaluated using Cox proportional hazards regres-
sion models to estimate the hazard ratio (HR) with 
95% confidence interval (CI), using three models 
adjusting for (a) age and gender, (b) multivariable 
adjustment including demographics, clinical char-
acteristics, and baseline comorbidities, and (c) with 
additional adjustment to RDW. 
We performed additional sensitivity analyses 
by repeating the multivariable models using the 
most adjacent lymphocyte count performed before 
coronary angiography instead of median 1-year 
levels, and by further adjusting the multivariable 
model to NLR, a marker of inflammation that was 
found to be independently associated with in-
creased risk of mortality in various cardiovascular 
diseases [18]. Exploratory analysis was performed 
by examining the association between lymphopenia 
and all-cause mortality stratified by the acuity of 
coronary presentation (STEMI, UAP/NSTEMI, 
non-ACS), and according to age decades, with 
calculation of p-values for interaction between 
subgroups. 
In order to further assess the association 
of lymphocyte count with mortality, absolute 
lymphocyte count was additionally modeled as 
a continuous variable. First, a linearity assumption 
on the relationship between lymphocyte count and 
mortality was tested using a likelihood ratio test, 
comparing two nested Cox regression models: 
one including only linear effect and the second 
including also quadratic and cubic terms, and the 
non-linearity was detected. Then, for graphical 
presentation of the association, a smoothed plot 
of adjusted HR (relative to a reference value of 
2000/μL, the overall median count) was estimated 
along with point-wise 95% CI. For this purpose, the 
lymphocyte count was flexibly modeled in a Cox 
regression using a restricted cubic spline function 
with five knots corresponding to the 5%, 25%, 
50%, 75%, and 95% percentiles of lymphocyte 
count [19]. We repeated the analysis separately 
for each of the three clinical presentation types: 
STEMI, UAP/NSTEMI, and non-ACS, and we 
tested the interaction between presentation type 
and lymphocyte count.
To assess the predictive accuracy of lympho-
cyte counts with and without the addition of RDW 
into a Cox regression model, Harrell’s concordance 
statistic was used, as implemented in the R survival 
package [20]. Concordance statistic along with 
standard error (SE) were presented, and further 
compared using appropriate Z contrast. 
The results were considered statistically sig-
nificant when the two-sided p-value was < 0.05. 
SPSS statistical software version 20.0, SAS version 
9.4 software, and MEDCALC version 16.8.4 were 
used to perform all statistical analyses. 
Results
A total of 15,179 patients undergoing coronary 
angiography for evaluation and/or treatment of 
CAD were included in the study. Their mean age 
was 65 ± 12 years, and 72% were males. Baseline 
patients’ characteristics are shown in Table 1, clas-
sified according to lymphocyte category (normal 
lymphocyte count, relative lymphopenia, and se-
vere lymphopenia). Compared to those with normal 
lymphocyte count, subjects with lymphopenia were 
older. The prevalence of chronic kidney disease, 
hypertension, prior cancer, vascular disease, con-
gestive heart failure, chronic obstructive lung 
disease, RDW levels, as well as presentation with 
ACS, increased with the reduction in lymphocyte 
count. In contrast, lymphopenia was associated 
with lower rates of hyperlipidemia, obesity, smok-
ing, and Arab ethnicity. 
The association between lymphopenia  
and mortality
Overall, 4253 (28%) patients died during 
a median follow-up of 8 years (IQR 4–12.2 years). 
Crude incidence rates of death increased pro-
gressively in patients with relative and severe 
lymphopenia compared to those with normal lym-
phocyte count, and in an inverse dose-response 
manner across lymphocyte quintiles: 7.16, 4.12, 
3.20, 2.76, and 2.37 events per 100 person-years, 
respectively (Table 2). Kaplan-Meier plots dis-
playing the distribution of time to mortality by 
the three lymphocyte categories are presented in 
Figure 1 (log rank p < 0.001). In a multivariable 
Cox proportional hazard regression analysis, the 
adjusted HR (95% CI) for long-term mortality was 
1.31 (1.21–1.41) for relative lymphopenia and 1.97 
(1.75–2.22) for severe lymphopenia, compared to 
subjects with normal lymphocyte counts (Table 2). 
In addition, compared to the highest lympho-
cyte quintile, the HRs for mortality increased 
in a graded manner (p for trend across quintiles 
< 0.001) and when analyzed as a continuous 
variable with an HR (95% CI) of 1.23 (1.17–1.29), 
p < 0.001 for each 100-lymphocyte cell count 
decrease. However, lymphocyte count appears 
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Figure 1. Long-term survival as a function of lymphocyte count.
Table 1. Patient characteristics according to lymphocyte count.














N = 565 (3.7%)
P
Age [years] 65 ± 12 64 ± 11 70 ± 11 73±11 < 0.001
Women 4359 (28.7%) 3448 (29%) 778 (28.4%) 133 (23.5%) 0.017
Hypertension 11088 (73%) 8542 (71.9%) 2097 (76.6%) 449 (79.5%) < 0.001
Hyperlipidemia 11021 (72.6%) 8696 (73.2%) 1945 (71%) 380 (67.3%) 0.001
Smoker 3495 (23%) 3114 (26.2%) 327 (11.9%) 54 (9.6%) < 0.001
Diabetes 5972 (39.3%) 4703 (39.6%) 1045 (38.2%) 24 (39.6%) 0.370
Ethnicity (Arab) 2801 (18.5%) 2438 (20.5%) 300 (11%) 63 (11.2%) < 0.001
Obesity 4726 (31.1%) 3929 (33.1%) 672 (24.5%) 125 (22.1%) < 0.001
Old myocardial infarction 8127 (53.5%) 6163 (51.9%) 1600 (58.4%) 364 (64.4%) < 0.001
Chronic kidney disease 1651 (10.9%) 1002 (8.4%) 492 (18%) 157 (27.8%) < 0.001
Creatinine > 1.4 mg/dL 1302 (8.6%) 769 (6.5%) 386 (14.1%) 147 (26%) < 0.001
PVD 992 (6.5%) 681 (5.7%) 252 (9.2%) 59 (10.4%) < 0.001
CABG 1725 (11.4%) 1270 (10.7%) 368 (13.4%) 87 (15.4%) < 0.001
ACS 8077 (53.2%) 6080 (51.2%) 1611 (58.8%) 386 (68.3%) < 0.001
Cancer 1684 (11.1%) 1042 9 (8.8%) 506 (18.5%) 136 (24.1%) < 0.001
Heart failure 2843 (10.7%) 1892 (15.9%) 725 (26.5%) 226 (40%) < 0.001
COPD 1088 (7.2%) 799 (6.7%) 225 (8.2%) 64 (11.3%) < 0.001
RDW median (IQR) 13.7 (13.2–14.4) 13.6 (13.1–14.3) 14.0 (13.3–14.7) 14.4 (13.6–15.6) < 0.001
WBC median (IQR) 7.9 (6.6–9.4) 8.1 (7.0–9.6) 6.8 (5.7–8.1) 6.7 (5.4–8.4) < 0.001 
ACS — acute coronary syndrome; CABG — coronary artery bypass graft surgery; COPD — chronic obstructive pulmonary disease; IQR —  
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to have a nonlinear reversed J-shaped relation-
ship with all-cause mortality (p for nonlinearity 
< 0.0001). A smoothed plot of adjusted HR (relative 
to the overall median lymphocyte value of 2000/μL) 
is presented in Figure 2.
The magnitude of the adjusted HR (95% CI) 
for death associated with severe lymphopenia 
decreased with increasing age (p for interaction 
< 0.001): 3.25 (2.24–4.71) in those aged ≤ 60 
years, 2.32 (1.73–3.12) in ages > 60 to 70 years, 
1.84 (1.53–2.22) in ages > 70 to 80 years, and 1.75 
(1.41–2.17) in patients aged > 80 years (Fig. 3). 
We reached similar results performing sen-
sitivity analysis, in which the association with 
mortality was evaluated using the most recent 
lymphocyte count tested before angiography in-
stead of the median values of all lymphocyte counts 
in the year prior to angiography (in this period 
a median of three tests [IQR 2–5 tests] were available 
for each patient): multivariable adjusted HR (95% 
CI) for mortality was 1.65 (1.48–1.83), p < 0.001 
for severe lymphopenia and 1.29 (1.20–1.39), 
p < 0.001 for relative lymphopenia. Moreover, the 
significant association of lymphopenia with mortal-
ity was retained after the addition of NLR to the 
multivariable model, both when added as median 
NLR levels: relative lymphopenia, HR 1.18 (95% 
Table 2. Crude incidence rates and multivariate Cox proportional regression models for the association 
between lymphocyte counts and long-term mortality.
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Relative lymphopenia 1073/2739  
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Continuous
HR is for each decrease of  







HR — hazard ratio; Q — quintile; RDW — red cell distribution width
Normal lymphocyte count > 1500/μL; relative lymphopenia 1000–1500/μL; severe lymphopenia < 1000/μL
*Adjusted for age, gender, ethnicity, hypertension, hyperlipidemia, smoking, diabetes, chronic kidney disease, obesity, cancer, chronic  
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Figure 2. Association between lymphocyte count and 
adjusted hazard ratio for mortality based on restricted 
cubic spline model, in the overall population.
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CI 1.10–1.28), p < 0.001 and severe lymphopenia, 
HR 1.45 (95% CI 1.25–1.69), p < 0.001 or as NLR 
tertiles: relative lymphopenia, HR 1.11 (95% CI 
1.02–1.20), p = 0.015 and severe lymphopenia, HR 
1.62 (95% CI 1.42–1.84), p < 0.001.
Lymphopenia and mortality, according  
to acuity of coronary presentation
Similar to the overall population, crude inci-
dence rates of death and adjusted HRs for mortality 
were higher in patients with relative lymphopenia, 
and more so in severe lymphopenia, compared to 
normal lymphocyte count, in each of the three 
coronary presentations (non-ACS, UAP/NSTEMI, 
or STEMI) (Fig. 4). Severe lymphopenia was as-
sociated with an adjusted HR (95% CI) for mortal-
ity of 2.18 (1.74–2.73) in patients with non-ACS, 
2.00 (1.70–2.34) in those with UAP/NSTEMI, and 
1.59 (1.15–2.21) in patients presenting with acute 
STEMI. The p-value for interaction between lym-
phocyte count and coronary presentation in rela-
tion to mortality was non-significant (p = 0.626). 
Supplementary Figure S1 further presents 
a smoothed plot of adjusted HRs for mortality 
according the coronary presentations based on 
restricted cubic spline model.  
RDW and refinement of mortality risk 
Red blood cell distribution width levels were 
higher in patients with lymphopenia (Table 1). The 
independent association between lymphopenia 
and mortality remained significant after further 
adjustment for RDW in the multivariable model, 
both in the overall study population (Table 2) and 
when separately analyzed in the three categories of 
coronary presentation (model 2 in Fig. 4). Survival 
probabilities over time in each of the lymphocyte 
count categories (normal lymphocyte levels, rela-
tive lymphopenia, or severe lymphopenia) were 
lower in patients with high RDW levels > 14.5% 
compared to those with RDW levels ≤ 14.5% 
(Suppl. Fig. S2). The discrimination ability of the 
lymphocyte count for mortality was improved with 
the addition of RDW count; the Harrell’s concord-
ance statistic significantly increased from 0.634 
(SE = 0.005) to 0.672 (SE = 0.005), p < 0.001 
for the change in the concordance statistic. The 
addition of RDW to lymphocyte count increased 
the discriminatory capacity for mortality in each 
of the three coronary presentations (STEMI: from 
0.623 [SE = 0.014] to 0.665 [SE = 0.0014]; UAP/ 
/NSTEMI: from 0.646 [SE = 0.007] to 0.688 
[SE = 0.006]; non-ACS: from 0.610 [SE = 0.008] to 
0.653 [SE = 0.008], p < 0.001 for all comparisons).
Discussion
In the present study we analyzed the associa-
tion between absolute lymphocyte count and long-
term mortality in patients presenting to coronary 
angiography in both the acute and non-acute set-
ting. Lymphopenia, especially when severe, was 
associated with increased long-term mortality, 
even after adjusting to chronic disease states such 
Table 3. Association of lymphocyte count with mortality according to age decades.
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CI — confidence interval; HR — hazard ratio
P for interaction between age and lymphocyte count < 0.001
*Adjusted for age, gender, ethnicity, hypertension, hyperlipidemia, smoking, diabetes, chronic kidney disease, obesity, cancer, chronic  
obstructive pulmonary disease, heart failure, peripheral vascular disease, previous myocardial infarction, acute coronary syndrome
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as cancer, heart failure, and vascular diseases, and 
regardless of the acuity of the coronary presenta-
tion. The magnitude of the increase in the risk of 
death associated with severe lymphopenia was 
more prominent in younger age groups. Moreover, 
elevated RDW levels were additively associated 
with reduced survival, and further refined risk 
prediction improving the discriminatory capacity 
of absolute lymphocyte count for mortality.
Lymphopenia is a common hematological 
finding observed in systemic inflammatory states, 
malignancies, and autoimmune diseases [1–5]. 
Early studies have shown that a low relative lym-
phocyte count, measured as the percentage of 
total leukocytes, is predictive of adverse out-
comes in CVD states, particularly heart failure 
[6–10]. Relatively few studies have evaluated 
absolute lymphocyte count as a prognostic bio-
marker, demonstrating its ability to stratify risk 
for mortality in the general population [11, 12]. 
Our findings extend the prognostic value of abso-
lute lymphopenia to patients undergoing coronary 
angiography for evaluation and/or treatment of 
CAD with both ACS and non-ACS. The increase 
in mortality seemed to be less pronounced in pa-
tients presenting with acute STEMI, although the 
interaction between lymphocyte count and coronary 
presentation was not statistically significant. Only 
a few analyses of very small-scale have evaluated the 
prognostic significance of lymphopenia in patients 
with CAD, including stable clinical presentation [21], 
unstable angina [22], mechanical complications after 
myocardial infarction [23], and no-reflow phenom-
enon [24]. In addition, total white blood cell count 
was shown to be an independent predictor of death 
and myocardial infarction in patients with, or at high 
risk of, CAD, with greater predictive ability provided 
by high neutrophil or low lymphocyte counts [13]. In 
the current analysis the increased mortality risk as-
sociated with lymphopenia remained significant after 
adjustment to NLR, demonstrating the independent 
predictive ability of absolute lymphopenia, which is 
more intuitive for bedside calculation than NLR.
Several mechanistic pathways may connect 
lymphopenia to adverse prognosis in CAD. Lym-
phocytes have been suggested to play a role in the 
Table 4. Association of lymphocyte count with mortality, according to coronary presentation.
Coronary presentation Normal lymphocyte count Relative lymphopenia Severe lymphopenia
Non-ACS
Deaths/at risk (%) 1288/5795 (22.2%) 381/1128 (33.8%) 86/179 (48%)
Model 1 Reference 1.30 (1.15–1.46) 2.18 (1.74–2.73)
P < 0.001 P < 0.001
Model 2 Reference 1.25 (1.11–1.41) 1.94 (1.55–2.44)
P < 0.001 P < 0.001
UAP/NSTEMI
Deaths/at risk (%) 1267/4753 (26.7%) 561/1292 (43.4%) 185/286 (64.7%)
Model 1 Reference 1.39 (1.25–1.54) 2.00 (1.70–2.34)
P < 0.001 P < 0.001
Model 2 Reference 1.33 (1.20–1.48) 1.81 (1.54–2.12)
P < 0.001 P < 0.001
STEMI
Deaths/at risk (%) 309/1327 (23.3%) 131/319 (41.1%) 45/100 (45%)
Model 1 Reference 1.10 (0.89–1.37) 1.59 (1.15–2.21)
P = 0.370 P=0.005
Model 2 Reference 1.05 (0.84–1.30) 1.54 (1.11–2.14)
P = 0.693 P<0.001
ACS — acute coronary syndrome; NSTEMI — non-ST-segment elevation myocardial infarction; STEMI — ST-segment elevation myocardial 
infarction; UAP — unstable angina pectoris
P for interaction between lymphocyte count and coronary presentation = 0.626
Model 1: Hazard ratios (95% confidence intervals) adjusted for age, gender, ethnicity, hypertension, hyperlipidemia, smoking, diabetes, 
chronic kidney disease, obesity, cancer, chronic obstructive pulmonary disease, heart failure, peripheral vascular disease, previous myocardial 
infarction
Model 2:  Hazard ratios (95% confidence intervals) adjusted as model 1 + red cell distribution width
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modulation of the inflammatory response through-
out the atherosclerotic process [25]. In response 
to physiologic stress there is a release of cortisol, 
catecholamines, and proinflammatory cytokines, 
which may lead to lymphopenia [26–28]. Activation 
of the immune system during myocardial ischemia 
or infarction may be accompanied by an increase 
of lymphocyte apoptosis, which was shown to be 
present in atherosclerotic lesions and becomes 
increasingly frequent with the development and 
destabilization of the atherosclerotic plaque [29]. 
Lymphopenia may also be aggravated by redistri-
bution of T cells from the circulation to lymphoid 
tissues [30]; it may induce compensatory prolifera-
tion of antigen-experienced T cells, which could 
increase the risk of cardiovascular disease [31]. 
On the other hand, an optimal lymphocyte count 
may reflect an immune system that is more capa-
ble of providing protection against cardiovascular 
diseases [12]. 
Lymphocyte count is known to decline with 
age [32], and this was also observed in the current 
analysis. Nevertheless, we found a higher relative 
risk for mortality associated with severe lympho-
penia in younger age groups, with a significant 
interaction between age and lymphocyte count in 
the context of mortality during long-term follow-
up. A similar trend was recently shown by Warny 
et al. [11] in the setting of the general population; 
it was suggested that additional factors including 
poor immune surveillance, blood transfusions, and 
iatrogenic causes such as medications might con-
tribute to the difference in mortality risk between 
age groups.
Red blood cell distribution width is a measure 
of red cell size variability. Its use in the clinical 
setting is mainly for the differential diagnosis of 
micro- and normocytic anemias [33]. However, 
in recent years multiple studies have shown sig-
nificant associations between RDW and clinical 
outcomes in a variety of populations, particularly 
cardiovascular morbidity and mortality [34, 35]. An 
elevated RDW may reflect chronic inflammation, 
ultimately leading to altered iron homeostasis and 
erythropoietin resistance. Associations between 
RDW, inflammatory markers, and impaired iron 
mobilization were demonstrated in heart failure 
[36, 37]. In the United Kingdom Biobank study, 
examining healthy volunteers, the incidence of 
CAD and all-cause mortality began to increase with 
RDW values > 13% and was the highest (3-fold 
higher) in participants with RDW value > 15% [38]. 
A meta-analysis of 21 studies concluded that high 
RDW levels are associated with increased risk of 
mortality and cardiovascular events also in patients 
with established CAD [39]. Zidar et al. [12] recently 
demonstrated in the setting of the general popula-
tion that the risks associated with abnormal immu-
nohematologic parameters including lymphopenia, 
RDW, and C-reactive protein may be synergistic 
with each other. Our findings are in line with these 
results, demonstrating improved risk prediction 
in patients with CAD when both lymphocytes and 
RDW levels are taken into account. 
Strengths and limitations
Strengths of the current analysis include the 
large number of CAD patients investigated with 
both acute and non-acute presentations and the 
long follow-up period. In addition, the classification 
of lymphocytes as both categorical and continuous 
variables may have reduced potential bias. Several 
limitations should also be noted. The study does 
not prove a causal relation between lymphopenia 
and mortality, due to its retrospective observational 
design. In addition, although significant adjustment 
was made for confounding variables including 
malignancies, heart failure, and other vascular 
diseases, we cannot exclude residual confounding. 
We did not account for infectious causes or auto-
immune diseases that are known to be associated 
with inflammatory markers. Parameters of immune 
activation such as C-reactive protein levels were 
not available, although we did adjust our data to 
NLR, an indicator of inflammation and oxidative 
stress that did not neutralize the independent as-
sociation of lymphopenia with mortality. Moreover, 
we used median levels of all lymphocyte counts in 
the year prior to angiography, and therefore our 
results may not reflect the association of lympho-
cyte count during ACS with mortality. However, 
we did perform sensitivity analysis using the most 
recent lymphocyte count tested before angiogra-
phy, achieving similar results. Finally, causes of 
death were not available, and therefore we could 
not evaluate the association of lymphopenia with 
specific causes of death.
Conclusions
Absolute lymphopenia, especially when se-
vere, may identify patients presenting to coronary 
angiography who are at higher risk for mortal-
ity during long-term follow-up. This association, 
observed in both acute and non-acute coronary 
presentations, was more significant in younger 
age groups and was aggravated in patients with 
elevated RDW levels enhancing the predictive 
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ability of lymphopenia. Routinely obtained immu-
nohematologic blood indices have potential utility 
in clinical practice as biomarkers for long-term risk 
prediction in patients with CAD.
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